Trial Profile

Phase II Study of MK-3475 in Conjunction With Lymphodepletion, TIL, and High or Low Dose IL-2 in Patients With Metastatic Melanoma

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 17 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Aldesleukin (Primary) ; Aldesleukin (Primary) ; Cyclophosphamide (Primary) ; Fludarabine (Primary) ; Pembrolizumab (Primary) ; Tumour infiltrating lymphocytes (Primary)
Indications Malignant melanoma; Skin cancer; Uveal melanoma
Focus Therapeutic Use

Most Recent Events

10 Apr 2024 Results (n=14) presented at the 115th Annual Meeting of the American Association for Cancer Research
27 Oct 2022 Status changed from active, no longer recruiting to completed.
29 Jun 2022 Planned End Date changed from 31 Aug 2022 to 31 Aug 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com